ArteraAI Prostate
Artera, Inc. · DEN240068
FDA-authorized Predetermined Change Control Plan
- Company
- Artera, Inc.
- 510(k)/De Novo #
- DEN240068
- Decision date
- 2025-07-31
- Panel
- Pathology
- Pathway
- De Novo
- Category
- AI/SaMD
- PCCP type
- Compatibility expansion
- Monitoring commitment
- Unknown
What this PCCP covers. Permits compatibility expansion to additional hardware
Other PCCPs from Artera, Inc.
Other Pathology PCCPs
- K254115ArteraAI BreastArtera, Inc.2026-05-04AI/SaMDModel update
- K243449INFINITT DPSInfinitt Healthcare Co., Ltd.2025-12-09Non-AIUnknown
- K252762HALO AP DxIndica Labs, LLC2025-11-25Non-AICompatibility expansion
- K243391AISight DxPathAI, Inc.2025-06-26Non-AICompatibility expansion
- K250968PathPresenter Clinical ViewerPathpresenter Corporation2025-06-20Non-AIUnknown
- K242244Viewer+Lumea, Inc.2025-03-14Non-AIUnknown
Want the monitoring teardown?
We read the PCCP for ArteraAI Prostate, then map the post-market monitoring that its modification protocol requires, including the deployment-period evidence most teams can't reconstruct at modification time. Sentir is the independent system of record that produces it.
Book a callSource: U.S. FDA public records (openFDA 510(k)/De Novo databases and accessdata.fda.gov). PCCP type and category are editorial classifications based on public documents, not official FDA designations.
This page is a factual summary of public FDA records. Sentir Health is not affiliated with or endorsed by the named companies or the U.S. Food and Drug Administration. Spot an error? Request a correction.